Sanda, MG, Smith, DC, Charles, LG, et al. Recombinant vaccinia-PSA (Prostvac) can induce a prostate- specific immune response in androgen-modulated human prostate cancer. Urology, 53:260-266, 1999 43. Eder, JP, Kantoff, PW, Roper, K, et al. APhase I trail of recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res, 6:1632-1638, 2000 44. Meidenbauer, N, Harris, DT, Spitler, LE, and Whiteside, TL. Generation of PSA -reactive effector cells after vaccination with a PSA -based vaccine in patients with prostate cancer. The Prostate, 43:88-100, 2000 45. Heiser, A, Coleman, D, Dannull, et al. Autologous dendritic cells transfected with prostate - specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest, 109:409-417, 2002 46. Gulley, J, Chen, AP, Dahut, W, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. The Prostate, 53:109-117, 2002 47. Kaufman, HL, Wang, W, Manola, J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol, 22:2122-2132, 2004 48. Pavlenko, M, Roos, A -K, Lundqvist, A, t al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Brit J Cancer, 91:688-394, 2004 49. Culley, JL, Arlen, PM, Bastian, A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res, 11:3353-3362, 2005 50. Small, EJ, Fratesi, P, Reese, DM, at al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol, 18:3894-3903, 2000 51. Fong, L, Brockstedt, B, Benike, C, at al. Dendritic cell -based xenogeneic vaccination for prostate cancer immunotherapy. J Immunol, 167:7150-7156, 2001 52. Rini, B Technology innovation: APC -8015, Dendreon. Curr Opin Molec Ther, 4:78 -79, 2002 53. Burch, PA, Croghan GA, Gastineau, DA, et al. Immunotherapy (APC8015, Provenge ®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A Phase 2 trial. The Prostate, 60:197-204, 2004 54. Tjoa, BA, Erickson, SJ, Bowes, VA, et al. Follow -up evaluation of prostate cancer patients infused with Autologous dendritic cells pulsed with PSMA peptides. The Prostate, 32:272- 278, 1997 55. Tjoa, BA, Simmons, SJ, Bowes, VA, et al. Evlauation of Phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. The Prostate, 36:39-44, 1998 56. Murphy, GP, Tjoa, BA, Simmons, SJ, et al. Infusion of dendritic cells pulsed with HLA -A2 specific prostate-specific membrane antigen peptides: A Phase II prostate cancer vaccine involving patients with hormone-refractory metastatic disease. The Prostate, 38:73-78, 1999 57. Vonderheide, RH, Domchek, SM, Schultze, JL, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res, 10:828-839, 2004 Lubaroff Ad/PSA Phase II, protocol #2, page 35 58. Su, Z, Dannull, J, Yang, BK, et al. Telomerase mRNA -transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate canc er. J Immunol, 174:3798-3807, 2005 59. Slovin, SF, Ragupathi, G, Musselli, C, et al. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with RF cluster (c) -KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol Immunother, 54:694-702, 2005 60. Slovin SF, Ragupathi, G, Musselli, C, et al. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: Clinical trial results with α-N-acetylgalactosamine-O- serine/threonine conjugate vaccine. J Clin Oncol, 21:4292-4298, 2003 61. Slovin, SF, Ragupathi, G, Adluri, S, et al. Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci, 96:5710 - 5715, 1999 62.